logo-loader

Pharmaxis reveals a quarterly shareholder update full of highlights

Published: 10:01 30 Apr 2018 AEST

Pharmaxis Ltd (ASX:PXS) chief executive Gary Phillips discusses with Proactive Investors the highlights contained within the biotech company’s latest Quarterly Shareholder Update.


“The one thing which really caught everyone’s attention was Boehringer Ingelheim starting a second indication with the drug they licensed from us,” notes Phillips. That development garnered a $15 million milestone payment.


Meanwhile, two compounds from the anti-fibrotic LOXL2 program have entered the clinic for phase one testing. The quarter also saw sales of Bronchitol improve in Europe and Australia.

Syntara to start Phase 2 study targeting MDS

Syntara Ltd (ASX:SNT) CEO Gary Phillips joins Proactive’s Jonathan Jackson to share insights on the company's expansion of its lead drug, SNT-5505, into new medical indications, including a promising Phase 2 study targeting myelodysplastic syndrome (MDS). Phillips highlighted the significance of...

on 14/2/24